BIAF | bioAffinity Technologies, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.9820 - 1.2900
52 Week Range	0.8310 - 3.62
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	476,156
Average Volume	140,190
Shares Outstanding	15,584,635
Market Cap	15,472,426
Sector	Healthcare
Industry	Medical - Diagnostics & Research
IPO Date	2022-09-01

Valuation
Profitability
Growth
Health
P/E Ratio	-1.24
Forward P/E Ratio	N/A
EPS	-0.80
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	75
Country	USA
Website	BIAF

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.

BIAF's peers: PRPO, STRR, TTOO, WLDSW, AQUNU, IDXG, INBS, SQL, BIOC, GENE, HTGM, GTH, PMD, BIAFW, KNW

*Chart delayed

Analyzing fundamentals for BIAF we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see BIAF Fundamentals page.

Watching at BIAF technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on BIAF Technicals page.